Despite category 4 subdivision providing better positive predictive value for biopsies, they are not done often enough.
Use of category 4 subdivisions in diagnostic mammography allowed for positive predictive value for biopsies performed (PPV3) to specify malignancy ranges, according to a study published in the journal Radiology.
Researchers from the University of Wisconsin School of Medicine and Public Health, in Madison; the American College of Radiology in Reston, Va.; and Stanford University School of Medicine in Calif., performed a retrospective review to determine the utilization and PPV of the American College of Radiology (ACR) Breast Imaging Data and Reporting System (BI-RADS) category 4 subdivisions in diagnostic mammography in the National Mammography Database (NMD).
The researchers reviewed data from 1,309,950 diagnostic mammograms submitted to the NMD from Jan. 1, 2008 to Dec. 30, 2014, and utilization rates of BI-RADS category 4 subdivisions were compared by year, facility (type, location, census region), and examination (indication, finding type) characteristics. PPV3 was calculated overall and according to category 4 subdivision. The Ï2 test was used to test for significant associations.
The results showed that of 1,309,950 diagnostic mammograms, 125,447 (9.6 percent) were category 4. Of these, 41,841 (33.3 percent) were subdivided. Subdivision utilization rates were higher in:
• Practices that were community, suburban, or in the West
• For examination indication of prior history of breast cancer
• For the imaging finding of architectural distortion
Breaking down the 41,841 category 4 subdivided examinations:
• 4A constituted 55.6 percent (23,258) of the examinations
• 4B constituted 31.8 percent (13,302) of the examinations
• 4C constituted 12.6 percent (5,281) of the examinations.
Pathologic outcomes were available in 91,563 examinations, and overall category 4 PPV3 was 21.1 percent (19,285). There was a statistically significant difference in PPV3 according to category 4 subdivision. PPV:
• 4A was 7.6 percent (1,274 of 16,784)
• 4B was 22 percent (2,317 of 10,408)
• 4C was 69.3 percent (2,839 of 4,099)
The researchers concluded that although BI-RADS suggests the use of subdivisions, they were utilized in the minority (33.3%) of category 4 diagnostic mammograms, with variability based on facility and examination characteristics. When subdivisions were used, PPV3s were in BI-RADS–specified malignancy ranges. This analysis supports the use of subdivisions in broad practice and, given benefits for patient care, should motivate increased utilization, they wrote.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.